NCT02385058View on ClinicalTrials.gov

Study to Evaluate Efficacy and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population

PHASE4CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

January 31, 2006

Study Completion Date

January 31, 2006

Conditions

HelminthiasisAmoebiasis

Interventions

DRUG

Mebendazole

Mebendazole 600 milligram (mg) tablet orally once starting on Day 1 and 21.

DRUG

Quinfamide

Quinfamide 200 mg tablet orally once starting on Day 1 and 21.

DRUG

Placebo

Placebo tablet orally once starting on Day 21.

Trial Locations (1)

Unknown

Mexico City

All Listed Sponsors

lead

Janssen-Cilag Ltd.

INDUSTRY

NCT02385058 - Study to Evaluate Efficacy and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population | Biotech Hunter | Biotech Hunter